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One of the visions of precision medicine has been to re‑define disease taxonomies based on molecular 
characteristics rather than on phenotypic evidence. However, achieving this goal is highly challenging, 
specifically in neurology. Our contribution is a machine‑learning based joint molecular subtyping 
of Alzheimer’s (AD) and Parkinson’s Disease (PD), based on the genetic burden of 15 molecular 
mechanisms comprising 27 proteins (e.g. APOE) that have been described in both diseases. We 
demonstrate that our joint AD/PD clustering using a combination of sparse autoencoders and sparse 
non‑negative matrix factorization is reproducible and can be associated with significant differences 
of AD and PD patient subgroups on a clinical, pathophysiological and molecular level. Hence, clusters 
are disease‑associated. To our knowledge this work is the first demonstration of a mechanism based 
stratification in the field of neurodegenerative diseases. Overall, we thus see this work as an important 
step towards a molecular mechanism‑based taxonomy of neurological disorders, which could help in 
developing better targeted therapies in the future by going beyond classical phenotype based disease 
definitions.
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MMSE  Mini-mental state examination
MOCA  Montreal Cognitive Assessment
MRI  Magnetic resonance imaging
NMF  Non-negative matrix factorization
PPMI  Parkinson’s progression markers initiative
PET  Positron emission tomography
PD  Parkinson’s disease
RBD  Rapid eye movement sleep behavior disorder
SNP  Single nucleotide polymorphism
UPDRS  Unified Parkinson’s disease rating scale
Many neurological disorders are highly multifaceted, heterogeneous and difficult to treat. The high percentages 
of clinical trial failures in Alzheimer’s Disease (AD) exemplify the unmet clinical need in the field: While Open 
Targets today lists 140 compounds that have been tested in clinical studies so  far1, there are currently only 4 
approved ones for symptomatic treatment on the  market2. The majority of clinical trial failures in neurology (like 
in other disease areas) can be attributed to a lack of efficacy, and one of the contributing factors is the selection 
of the wrong target  population3.
Precision medicine brings the hope of disentangling diseases into separate molecular subgroups, which could 
be therapeutically targeted more specifically, hence increasing the chances of successful treatment. Moreover, 
these molecular subtypes may be associated with particular mechanisms, which might allow the identification of 
novel treatment opportunities. The far-reaching vision is an entirely molecular defined taxonomy of neurological 
disorders, which should be seen in contrast to the traditional and purely phenotypic way, in which neurological 
diseases have been defined since the nineteenth  century4,5.
The AETIONOMY project funded within the Innovative Medicines Initiative (IMI) of the European Union 
has taken a step into this direction (www.aetio nomy.eu). While focusing on Alzheimer’s and Parkinson’s Disease 
(PD) as important examples, the goal of AETIONOMY was to identify and validate molecular characteristics that 
could help to stratify AD and PD into more homogeneous patient subgroups. Both neurodegenerative diseases 
share common properties, such as  neuroinflammation6, aberrant miRNA  expression7, and protein  misfolding8. 
Accordingly, it has been suspected for a long time that, despite largely non-overlapping causal genetic vari-
ants in genome-wide association studies (GWAS), similarities may be expected at the functional or molecular 
mechanism  level9–11. Hence, some authors have suggested to focus the analysis on functional categories rather 
than on individual genetic  variants10.
The existence of commonly impaired biological processes or mechanisms is also potentially attractive from a 
therapeutic point of view, since it might open the perspective for a more causal disease treatment. However, the 
question arises, how homogenous AD and PD patient groups might be with respect to those shared mechanisms, 
i.e. whether there exist subgroups.
In this work, we explored the genetic burden by single nucleotide polymorphisms (SNPs) on genes that in 
the literature have been described to play a role in both diseases. We found that, based on aggregate SNP burden 
scores of common molecular mechanisms in AD and PD, unsupervised machine learning methods can identify 
distinct and reproducible joint subgroups. We show that these clusters can be associated with distinct clinical, 
pathophysiological and molecular features on a biological-processes and pathway level, and we investigate the 
potential clinical utility of these differences by prioritizing drug targets for specific patient subgroups. Altogether, 
this work shows the possibility of effectively using knowledge about disease mechanisms in combination with 
modern machine learning techniques to unravel molecular subtypes of AD and PD, which may in the future 
aid the development of better targeted therapies by contributing to a molecular mechanism-based definition of 
neurodegenerative diseases.
Results
Strategy for identifying mechanism based AD/PD subtypes. Before going into more detail, we 
briefly outline our general approach for identifying subtypes of sporadic AD and PD idiopathic patients (Fig. 1): 
Following Tan et al.12 it is largely driven by the idea of a genetic sub-classification followed by a clinical, imaging 
based and biological characterization of patients in each cluster to test disease relevance.
Genetic commonalities between AD and PD can only be expected at the biological function level. Hence, the 
starting point of our work was a comprehensive mapping of the molecular disease landscape of AD and PD based 
on the scientific literature (see “Methods” section). The result was a set of 15 molecular mechanisms comprising 
27 proteins that have been implicated in both diseases (Fig. 2). We mapped 148 SNPs to these genes based on 
proximity as well as eQTL analysis, see details in Supplements. Using ADNI and PPMI as discovery cohorts (see 
descriptions in “Methods” section), we calculated for each of the 15 molecular mechanism an aggregate burden 
score via sparse autoencoders and then used sparse non-negative matrix factorization to identify 4 distinct patient 
subgroups in AD and PD, see “Methods” section. These subgroups were found independently in both diseases 
as well as in a merger of ADNI and PPMI patients (Fig. 3A–C).
As a next step, we validated the existence of the identified mixed AD/PD subgroups with the help of dis-
ease patients in our integrated AETIONOMY AD and PD cohorts (see description in “Methods” section and 
Fig. 3D–F). Finally, we tested the disease relevance of the patient subgroups by statistically analyzing the dif-
ferences of clinical and brain imaging related features as well as transcriptome and methylome profiles in AD 
and PD patients. Following this high-level overview about our strategy, we will now describe each of the main 
analysis steps in more detail.
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Figure 1.  Strategy for identifying AD + PD subtypes.
Figure 2.  Common AD/PD disease mechanisms, see also https ://clus2 bio.scai.fraun hofer .de/mecha nisms .
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Mechanism burden scores allow for reproducible subtyping of AD and PD patients. Using the 
data of 148 SNPs mapping to 15 common AD/PD disease mechanisms in 486 AD and 358 PD patients within 
our discovery cohorts, we developed an unsupervised machine learning approach to discover subgroups (see 
details in “Methods” section and Supplementary Text p. 13). This approach consisted of two basic steps: (i) 
sparse autoencoding of the SNPs mapping to each of the 15 mechanisms, resulting into a profile of genetic 
burden scores; (ii) consensus sparse non-negative matrix factorization to cluster patients and for identifying 
most discriminative mechanisms. Our method resulted in 4 subgroups in ADNI, PPMI as well as in a merger 
of ADNI and PPMI patients that were statistically stable and better discriminated than expected by pure chance 
(Fig. 3A-C, Tables S2–S4); details are described in the “Methods” section and in the Supplementary Text (p. 28). 
Interestingly, clusters found in the merged AD/PD cohort were all composed of a mixture of AD and PD patients 
(Figure S22). They were not identical to the ones identified in each disease individually, but showed a highly 
significant overlap in both cases (p < 1E−16, χ2-test). That means our clustering suggests the existence of certain 
commonalities between AD and PD patients on the level of SNP burden on specific mechanisms. We will discuss 
the question of disease relevance later.
Due to the particular properties of our employed clustering approach, each of the clusters can be linked back 
to a particular set of disease mechanisms (Figure S21, Table S1 and https ://clus2 bio.scai.fraun hofer .de/mecha 
nisms for an interactive view): Cluster 1 reflects the genetic burden on AKT1. AKT1 phosphorylation regulates 
multiple signaling cascades that are of relevance in both AD and  PD13–15.
Cluster 2 is—among other features—strongly associated with the genetic burden on IL1B, NLRP3,  TP5316–19. 
Activation of IL1B by NLRP3 and TP53 play a role in the response of the immune system. Neuroinflammation 
is a common feature of AD and  PD6.
One of the features of cluster 3 is the genetic burden on MTHFR, which is implicated in hydrogen peroxide 
and homocysteine regulation as well as cell death and oxidative  stress20, Genetic variants may contribute to the 
risk of  PD21 and late-onset of  AD22,23.
Cluster 4 reflects the genetic burden on MAPK9, which is implicated in multiple signaling cascades in both 
 diseases24,25.
Again, these are only examples of representative mechanisms for each cluster. A complete overview can be 
found in Table S1 and under https ://clus2 bio.scai.fraun hofer .de/mecha nisms .
Our next steps particularly focused on the validation of the existence of the joint AD/PD subgroups. For 
this purpose, we made use of a merger of our integrated AETIONOMY AD and PD validation cohorts, and we 
asked two essential questions:
Figure 3.  Identification of mechanism-induced subtypes in AD and PD: (A) Consensus clustering of ADNI AD 
patients (consensus matrix). (B) Consensus clustering of PPMI PD patients (consensus matrix). (C) Consensus 
clustering of merged ADNI + PPMI (consensus matrix). (D) Consensus clustering of merged validation data 
(integrated AETIONOMY AD + PD, consensus matrix). (E) Prediction performance of a classifier that allows 
assigning each patient in a validation cohort to a cluster in the discovery cohort. (F) Coherence of joint AD + PD 
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1. Does an independent clustering of patients in the validation data re-suggest the same number of clusters?
2. Given the panel of 148 SNPs, can we put patients from our validation cohorts into the same clusters that we 
had previously identified based on our discovery cohorts, and is the correspondingly induced stratification 
of patients in the validation cohorts coherent with the clustering of patients in the discovery data?
To answer the first question, we re-ran our developed unsupervised machine learning approach (consisting of 
sparse autoencoding of each of the 15 molecular mechanisms followed by consensus sparse non-negative matrix 
factorization), which again supported the existence of 4 clusters composed of mixture of AD and PD patients in 
the merged validation data (Fig. 3D, Table S5, Figure S23).
To answer question two, we first developed a predictive machine learning algorithm, which allowed us to 
assign any patient in a validation cohort to one of the established clusters (see “Methods” section). Cross-vali-
dation based evaluation of the prediction performance of this classifier was conducted and indicated a decent 
area under receiver operator characteristic curve (AUC) of ~ 70% that was significantly higher than chance level 
(Fig. 3E), i.e. clusters were predictable.
Secondly, we measured the coherence of the predicted stratification of patients in our validation cohorts with 
the one identified in our discovery cohorts. This was done by counting the fraction of patients in the validation 
cohort whose closest patient in the discovery cohort had the same label, yielding the In-Group Proportion (IGP) 
measure suggested by Kapp and  Tibshirani26, see “Methods” section for details. Accordingly, we could verify a 
high and statistically significant agreement of clusters predicted for patients in the validation data with those in 
the merged discovery cohort (Fig. 3F). Overall, we thus concluded that our discovered joint stratification of AD 
and PD patients was reproducible.
Comparison of clinical outcome measures between clusters. Our next steps focused on the ques-
tion whether our identified patient clusters were disease associated or just reflecting general genetic differences 
in the population. For this purpose, we used clinical, imaging, transcriptome and methylome data.
We first investigated differences in clinical outcome measures of AD and PD patients across clusters. This 
was done separately on the basis of each of the individual study used in this paper (AD: ADNI, ROSMAP; PD: 
PPMI, AETIONOMY PD, ICEBERG, DIGPD), because available clinical data differs between studies (Tables 1, 
2), and differences in inclusion/exclusion criteria may bias a combined analysis: Despite the fact that all patients 
had a time till initial diagnosis of at most 2 years there were significant differences of baseline UPDRS scores 
between PD studies (p < 1E-9 for MDS-UPDRS I, p = 0.02 for MDS-UPDRS II, p < 1E-5 for MDS-UPDRS III off 
treatment score; Kruskal–Wallis test), and in all cases UPDRS total (sum of MDS-UPDRS I + II + III off treat-
ment scores) in PPMI and DIGPD were lower than in AETIONOMY PD and ICEBERG (median UPDRS total 
in PPMI: 30, DIGPD: 33, AETIONOMY PD: 42, ICEBERG: 47). Similarly, AD cohorts differed significantly by 
age (p < 2E−16, one-way ANOVA), level of education (p < 0.01, Kruskal–Wallis test) and MMSE baseline scores 
(p < 1E−10, Kruskal–Wallis test).
Based on these observations we focused on a statistical analysis within each of the AD and PD cohorts sepa-
rately. Notably, IDIBAPS was excluded at this point due to the very small sample size (only 29 cases). Summary 
statistics of major demographic and clinical baseline variables of all clusters in AD and PD can be found in 
Tables S7 and S8. Within ADNI we compared multiple cognitive assessment scores (CDRSB, ADAS11, ADAS13, 
MMSE, MOCA, FAQ, RAVLT, and LDELTOTAL) at the visit of first dementia diagnosis (n = 486 patients) across 
Table 1.  Demographic and clinical variable summary of AD discovery (ADNI) and validation (ROSMAP and 
IDIBAPS) cohorts. The data shows only clinically diagnosed sporadic AD cases. The Table shows the median of 
each variable and the inter-quartile range (IQR) in brackets.





ADNI 75.55 (9.6) 288/198 16 (5) 24(3) 4.5 (2) 17 (8.33) 27.67 (10) 23 (9) 2 (2)
ROSMAP 87.98 (6.19) 52/142 16 (5) NA NA NA NA NA NA
IDIBAPS 62.42 (9.75) 15/28 12 (9) 18 (7.5) NA NA NA NA NA
Table 2.  Demographic and clinical variable summary of PD discovery (PPMI) and validation (AETIONOMY 
PD, DIGIPD, ICEBERG) cohorts. The data shows only de novo diagnosed idiopathic PD cases. The Table 
shows the median of each variable and the inter-quartile range (IQR) in brackets.
Cohort Age
Gender 





PPMI 62.5 (14.14) 238/120 5 (5) 5 (6) 19 (11.75) NA 28 (3) NA NA
AETION-
OMY PD 64 (11.25) 59/29 7 (6.75) 7 (8.75) 28 (17) 0 (0) 27 (4) 5 (5) 2 (0)
DIGPD 61 (12) 100/73 7 (6) 5 (5) 21 (11) 0 (0) NA 6 (4) 2 (1)
ICEBERG 67 (16.5) 30/12 10 (4) 7 (6) 29.5 (11.5) 0 (0) 27 (3) 7 (3) 2 (0)
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clusters. The provided cognitive tests cover different aspects, such as global cognitive impairment (ADAS11, 
ADAS13, MMSE, MOCA), logical memory (LDELTOTAL), verbal episodic memory (RAVLT) and activities 
of daily living (FAQ). For more detailed information about the composition of individual cognition scores we 
refer to the  literature27–32. Notably, cluster labels were based on the clustering of the merged ADNI + PPMI and 
ROSMAP + AETIONOMY PD + ICEBERG + DIGPD cohorts, respectively. Statistical significances were corrected 
for multiple confounding factors, such as age, gender, time until diagnosis, ethnicity and the use of L-DOPA (the 
latter for PD patients). Multiple testing correction was applied via the method by Benjamini and  Hochberg33. 
Details about the statistical analysis are described in the “Methods” section part of this paper.
According to our analysis, no statistically significant differences of cognitive assessment scores could be found 
between clusters in AD patients at study baseline (although we notably did observe weakly significant results 
for working memory cognition assessments in ROSMAP patients). However, as indicated in Fig. 4A–D, PD 
patients in AETIONOMY PD and ICEBERG demonstrated significant pairwise differences between clusters with 
respect to several clinical baseline scores, namely MDS-UPDRS I (non-motor aspects of daily living; ICEBERG, 
AETIONOMY PD), HADS anxiety score (ICEBERG), MDS-UPDRS III (motor examination) on treatment 
scores (ICEBERG) and Schwab-England Scale (difficulties with activities of daily living; AETIONOMY PD). No 
significant results were found in PPMI and DIGPD.
In addition to this analysis of baseline variables we also conducted an analysis of follow-up longitudinal data, 
which was available in ADNI (AD) and PPMI (PD) cohorts. This analysis showed significant differences of the 
progression of MDS-UPDRS III (motor examination) scores across patient subtypes in PPMI. In ADNI we found 
significant differences in the progression of global cognitive impairment (ADAS11, ADAS13, CDRSB, MMSE) 
and verbal episodic memory (RAVLT; see Tables S12, S13).
In summary, clusters are associated with significant differences of clinical disease symptoms and symptom 
progression of AD and PD patients.
Association with brain imaging derived features in AD and PD. In ADNI, AD patients demon-
strated highly significant pairwise differences when comparing 193 intracranial volume normalized subcortical 
Figure 4.  Examples of significant differences between clusters with respect to clinical baseline features 
in PD patients after correction for confounding effects (see “Methods” section). (A) MDS-UPDRS I score 
(AETIONOMY PD); (B) MDS-UPDRS III on treatment score (ICEBERG); (C) HADS anxiety score 
(ICEBERG); (D) Schwab-England Scale in % (AETIONOMY PD). The Figures shows statistical distributions as 
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brain structures of those patients which had a recent AD diagnosis at study baseline (n = 209) and correcting 
statistical differences for the confounding effects of age and sex. We found significant differences in several 
brain regions, such as the calcarine sulcus, the cuneus gyrus and the medial occipitotemporal gyrus (Table S14, 
Fig. 5A–C).
In PPMI, pairwise differences between the clusters were significant for in presynaptic dopaminergic imaging 
(DaTSCAN) were identified in caudate and putamen (Table S16, Fig. 5D–F). Also, the dopamine receptor density 
ratio of caudate versus putamen differed significantly between clusters.
Altogether, we concluded that our genetically derived clusters are associated with significant pathophysi-
ological differences in the brain.
Association with A‑β , transcriptome and methylome changes. Interestingly, the CSF protein A-β 
showed significant pairwise concentration differences between all clusters in PPMI PD patients (Table S16), but 
not in ADNI AD subjects. However, there was only weakly significant difference in MOCA cognitive assessment 
scores across clusters (p = 0.1) and no correlation of A-β levels with MOCA (p = 0.53, Kendall’s tau: 0.03). This is 
in agreement with Melzer et al.34, who reported no association of amyloid-beta deposits with cognitive decline 
in PD patients.
We further explored changes in transcriptome and methylome of ROSMAP AD patients on the level of Gene 
Ontology (GO)  terms35 and KEGG  pathways36 via Gene Set Enrichment Analysis (GSEA)37. This analysis was 
chosen due to the low sample size, and it can only reveal broad trends in the data, namely statistical enrichment 
of GO terms and pathway at the beginning or end of a fold change ranked list of genes. We here report findings 
of GO terms and KEGG pathways that were statistically enriched within one particular patient subtype, but not 
in others compared to cognitively normal controls. Enrichment  maps38 were used to provide a condensed view 
on biological processes and pathways that were particularly altered within one specific cluster (Figure S25–S41). 
Enrichment maps represent semantic similarities between GO terms (shown as nodes) via edges, and group GO 
terms together based on the hierarchical relationship between them. More results (including comparisons of one 
specific cluster to all others) can be found under https ://clus2 bio.scai.fraun hofer .de).
According to the highly condensed view of enrichment maps, for example, cluster 1 in AD specifically shows 
changes in the meiotic cycle compared to healthy donors (Figure S26). In fact, aberrant re-entry of neurons into 
the cell cycle has long been seen as one of the hallmarks of  AD39,40. Cluster 2 shows transcriptome changes in 
microtubule-based processes (Figure S27). Indeed, the tau protein, which under healthy conditions stabilizes 
microtubule, in AD patients aggregates into insoluble filaments in the brain that represent one of the hallmarks of 
the  disease41. Specific features of cluster 3 are gene expression changes of processes related to the termination of 
Figure 5.  Example of significant differences between clusters with respect to brain imaging derived features at 
study baseline/time of first disease diagnosis (see “Methods” section). (A) left calcarine sulcus in AD patients; 
(B) left cuneus gyrus in AD patients; (C) volume of right medial occipitotemporal gyrus in AD patients; (D) 
DaTSCAN left Putamen—ratio to age expected value in healthy controls; (E) DaTSCAN Count Density Ratio: 
Caudate/Putamen; (F) DaTSCAN Count Density Ratio (CL): Caudate contralateral/Putamen contralateral. The 
Figures shows statistical distributions as violin plots (i.e. boxplots plus kernel density estimates), and individual 
data points are shown as superimposed dots.
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protein translation (Figure S28). Reduced global translation rates (and RNA levels) have been observed previously 
in AD  patients42. Alteration of apoptosis related pathways is one of the features specific for cluster 4 (Figure S29), 
which is well known in the context of  AD43. In addition, patients in this cluster show DNA methylation changes 
in growth factor beta receptors (Figure S35), which has been reported to promote AD  pathology44. More results 
can be found in the Supplements.
PPMI transcriptome and methylome data has a larger sample size, but the main limitation is the fact that 
measurements have been derived from blood and thus only indirectly mirror the pathological processes in the 
brain. Accordingly, we here again decided to only focus on GSEA results comparing PD patients in each of the 
clusters against healthy controls (S30–S32; S37–S41). For example, cluster 1 shows specific methylome changes 
in the JAK-STAT signaling pathway. Inhibition of this pathway has been suggested as a therapy against  PD45. 
Cluster 2 shows methylome changes of microtubule cytoskeleton organization. Tau deposition and filament 
assembly is one of the hallmarks of  PD46. Assembly of misfolded proteins in PD yields activation of adaptive 
immune  response47. According, transcriptional changes can be observed in cluster 2 as well. Cluster 3 demon-
strates methylome changes of lipoprotein metabolism, which has recently been found altered in  PD48. Cluster 4 
shows transcriptional changes in protein ubiquitination, which has been suggested to also play a role in idiopathic 
forms of  PD49,50. In addition, methylome changes of several metabolic processes were observed, which is in agree-
ment with recent findings that view PD as a disorder of the cell  metabolism51. Again, more results (including 
enrichment maps for GO terms) can be found in the Supplements and under https ://clus2 bio.scai.fraun hofer .de.
Altogether, our examples suggest that—despite the obvious limitations of the employed molecular data—each 
of the four clusters can be associated with biological processes that are solely enriched in one cluster and that 
are well known in the context of both diseases. Epigenetic changes were observed to a much higher extent in 
PD than in AD.
Molecular differences between clusters can be linked to known disease mechanisms. We next 
explored GO terms (biological processes) and KEGG pathways that were enriched in the difference between one 
cluster to all others. In other words, we looked into differential expression and differential methylation between 
cluster 1 and all others, cluster 2 and all others, and so on. For each of these comparisons a larger number of bio-
logical processes and pathways could be identified in both AD and PD (Tables S18, S20, S22, S24). In agreement 
to the findings in the last Section, significant differences between clusters in methylation could only be found in 
PD patients, but not in AD. Transcriptome differences between clusters were observed in both diseases.
We further explored the link between differences at the transcriptome and methylome level among clusters 
and known disease mechanisms in AD and PD. More specifically, we mapped our initially identified 15 common 
AD/PD disease mechanisms to disease specific mechanisms defined in the NeuroMMSig  database52. That means, 
each of the common AD/PD mechanisms used in our clustering was identified with a certain NeuroMMSig 
gene set, if it was contained in that gene set. We found at least one NeuroMMSig gene set for each of the 15 
mechanisms. Since each NeuroMMSig gene set equals a subgraph in one of our literature derived AD and PD 
disease maps (see “Methods” section), we could then systematically conduct graph mining. More specifically, 
we looked for shortest paths linking NeuroMMSig gene sets with biological processes and pathways identified 
in our omics data analysis. Shortest path calculations considered the causal direction of edges (marking e.g. a 
phosphorylation event) whenever possible. Due to the large number of results (over 600), we decided to imple-
ment an interactive web application for exploration (https ://clus2 bio.scai.fraun hofer .de/bioma rkers ). The web 
application also provides pointers to the scientific literature supporting each of the edges.
In the following, we highlight only selected examples (Fig. 6): As explained previously, cluster 1 is strongly 
associated with the genetic burden on AKT signaling. At the transcriptional level we observed significant down-
regulation of genes in the cell cycle process in AD patients (adj. p value 0.03). Both can be linked together, as 
shown in Fig. 6A. AKT signaling influences acetylcholinesterase (AChE), which is thought to play a role in 
apoptotic  processes53 and amyloid-beta  formation54. Amyloid-beta increases NAE1 via  APP55 and influences 
the entire cell cycle  process56.
In cluster 2, for PD patients we observed differential methylation of genes involved in processes related to 
microtubule cytoskeleton organization (adj. p value < 0.001). Cluster 2 is—among others—associated with the 
genetic burden on TP53. As shown in Fig. 6B there is indeed a causal chain between TP53 and microtubule 
cytoskeleton organization. Elevated TP53 levels have been found to induce apoptosis and inflammation in  PD57. 
Apoptotic processes yield a translocation of UTRN from the cytosol to mitochondria and subsequently increases 
cytochrome  C58 and alpha-syn59, which itself is involved in microtubule cytoskeleton  organization60.
In cluster 3, for AD patients we observed significant transcriptional downregulation of genes involved in 
“long term synaptic depression” (adj. p value 0.02). Cluster 3 is at the same time associated to the genetic burden 
on APOE. The connection between both is highlighted in Fig. 6C. For example, APOE has been suggested to 
increase insulin  resistance61, which yields synaptic depression of neurons and thus suggests the perception of 
AD as a “type 3 diabetes”62.
Once again, these are only examples and further results can be explored via our web application.
Potential implications for drug development. Our previous results indicate that our AD/PD cluster-
ing can be associated with molecular and pathophysiological differences between patient subgroups. To better 
understand the potential utility of these patient subgroups for improving future AD and PD therapy, we con-
ducted a target prioritization of all 27 genes involved into the 15 mechanisms that we had previously used in 
conjunction with SNP data to identify cluster patients. Target prioritization was done via Open  Targets1, which 
uses genetic evidence as well as literature mining to assign a confidence score to each protein as a potential drug 
target. In addition, tractability by small molecules and antibodies was considered. Figures S41, S42 highlight that 
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in both diseases several potential targets could be identified via Open Targets. In addition, some of these targets 
could be clearly associated to one specific cluster (Table S1): In AD genes CDK5, GSK3B are strongly associated 
to cluster 2 (Table S1). APOE, PICALM, TOMM40, MTHFR and CD33 are linked to cluster 3. Further potential 
targets include SNCA, IL6 and CYCS, which are more strongly associated with clusters 2 and 3 than to the rest.
In PD, only SNCA, MAPT and APOE were identified as potential targets (Figure S42). MAPT is strongly 
associated with cluster 2 and APOE to cluster 3 (Table S1).
Altogether this analysis shows that our patient subtypes might be used to inform better targeted therapeutic 
strategies in AD and PD in the future.
Conclusion
Precision medicine offers the hope of delivering the right treatment to the right patient, based on individual 
characteristics rather than population averages for these characteristics. Precision medicine is only an emerg-
ing reality at this moment, and moving closer to this vision will require non-trivial efforts in data mining and 
machine learning based on the entirety of available patient  data63. Specifically, in neurology, this is extremely 
challenging, because on the one hand diseases are often highly multifaceted and on the other hand deep molecu-
lar multi-omics data (as frequently employed in cancer research) are difficult or even impossible to obtain for 
obvious reasons. Accordingly, in this work we started with an intensive literature mining effort, which mapped 
out the current mechanistic understanding of AD and PD pathologies and allowed us to identify shared molecular 
mechanisms. These shared molecular mechanisms were used as a starting point for developing a joint molecular 
subgrouping of AD and PD. More specifically, we used state-of-the-art unsupervised machine learning techniques 
to identify four mixed AD + PD patient clusters based on SNP burden scores of common AD/PD mechanisms. 
Importantly, the resultant disease subtypes manifest as mixtures of different mechanisms rather than being 
instances of single ones.
We validated the existence of patient clusters based on combined genotypes of 561 patients from AETION-
OMY PD, ICEBERG, DIGPD, ROSMAP and IDIBAPS studies. Moreover, we conducted an in-depth analysis of 
clinical, imaging and molecular differences between patient clusters in both diseases. Our work demonstrated 
that SNP burden on mechanism level can be used to subdivide AD as well as PD patients jointly, and that clusters 
are associated with clinical, pathophysiological (specifically visible in brain imaging) and molecular differences 
between patients. We investigated the potential clinical utility of these differences by prioritizing drug targets 
for specific patient subgroups.
Overall, one should see our approach as complementary to the multitude of existing work that focuses on 
separate subgrouping of AD and PD based on polygenic risk  scores64, CSF, blood and imaging  biomarkers65–67, 
or based on clinical outcome  measures68,69. We see the main distinction of our approach in a better understand-
ing of the stratification potential of common AD and PD disease mechanisms, including the implications for 
future drug development.
Figure 6.  Examples of GO terms (biological processes) found significantly enriched in gene expression and/
or methylome changes of one cluster compared to all others (yellow) together with their connections to 
genes playing a role in common AD/PD disease mechanisms (red): (A) Connection between AKT signaling 
(feature of cluster 1) and cell cycle in AD; (B) connection between TP53 (features of cluster 2) and microtubule 
cytoskeleton organization in PD; (C) connection between APOE4 (feature of cluster 3) and long term synaptic 
depression in AD. Intermediate signaling proteins are shown in blue. For more examples visit https ://clus2 bio.
scai.fraun hofer .de/bioma rkers .
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Of course, our work is not without limitations: These can largely be associated to the limited availability of 
transcriptome and methylome data (with matched SNP genotypes from the same patient) in only two studies 
(ROSMAP and PPMI) and with relatively low sample sizes in ROSMAP. Moreover, clinical differences between 
cohorts imposed non-trivial challenges for reaching coherent conclusions regarding the clinical differences 
between patient subgroups. We thus see a need to more systematically replicate observational clinical studies 
in the neurology field. At the same time, such studies should preferably be longitudinal and collect multi-omics 
data from the same patient in a more systematic way than currently done in ROSMAP and PPMI. Such data 
should then be used to re-validate the findings presented here, specifically in terms of molecular differences 
between patient subgroups.
Altogether, we see our work as a step towards realizing the far-reaching vision of a completely molecular based 
definition of human disease, as formulated by Kola and  Bell4 and Strafella et al.5. As pointed out before, we see 
the potential impact of such an effort in the development of better targeted and thus hopefully more efficacious 
therapies in AD and PD in the future.
Materials and methods
Overview about used data. Studies used for discovery. ADNI. Data were obtained from the Alzhei-
mer’s Disease Neuroimaging Initiative (ADNI) database (www.adni.loni.usc.edu). The longitudinal observation 
study includes—among others—486 subjects, which were diagnosed with mild sporadic AD during the study. 
206 patients had a recent clinical AD diagnosis at study baseline. Data from ADNI subjects includes SNP based 
genotype (two different Illumina chip platforms), APOE4 status, CSF biomarkers, volume measurements of 
seven brain regions as well as different clinical and neuropsychological test results. In addition to the 7 brain 
volume measurements provided in the original ADNIMERGE dataset we calculated 193 subcortical brain region 
volumes from raw images, using the parcellation by Destrieux et al.70, see details in Supplements. An overview 
about key demographic and clinical features of this study can be found in Table 1.
PPMI. The Parkinson’s Progression Markers Initiative (PPMI) (www.ppmi-info.org/data) consists of multiple 
cohorts from a network of clinical sites with the aim to identify and verify progression markers in PD. It is 
a longitudinal observation study with data collected using standardized  protocols71. PPMI comprises of eight 
cohorts with different clinical and genetic characteristics. Here we used data of 358 de novo diagnosed idi-
opathic PD patients and 198 healthy controls. All PD patients were initially untreated and diagnosed with the 
disease for two years or less. The dataset contains information about patient demographics, patient PD history, 
DaTSCAN imaging, non-motor symptoms, CSF biomarkers (A-β , α-synuclein, dopamine, phospho-tau, total 
tau) and UPDRS scores. Genotype was available via whole genome sequencing data. In addition, whole blood 
transcriptome and methylome data was available for n = 306 and n = 277 of the same patients, respectively. The 
number of healthy controls with available gene expression and DNA methylation data was n = 151 and n = 112. 
An overview about key demographic and clinical features of this study can be found in Table 2.
Studies used for validation. Integrated AETIONOMY AD. Validation data comprised 237 clinically diag-
nosed sporadic AD cases with available genotype from  ROSMAP72 (n = 194) and 21 additional cases with avail-
able genotype from IDIBAPS taken from the AETIONOMY biomarker verification  study73. We call the union of 
these 258 AD patients integrated AETIONOMY AD in the following. The data included:
• clinical characteristics: e.g. post-mortem diagnosis, age at death, gender
• genome-wide transcriptome (n = 56 AD cases with jointly available genotype and n = 50 cognitively normal 
controls) and methylome data (n = 53 AD cases with jointly available genotype and n = 34 cognitively normal 
controls) from post-mortem brain tissue (ROSMAP)
An overview about key demographic and clinical features of this study can be found in Table 1.
Integrated AETIONOMY PD. Validation data comprised idiopathic PD cases with available genotype that 
were diagnosed with PD for 2 years or less (in agreement to PPMI). 173 out of the 303 cases stem from DIGPD 
(NCT01564992)74, 42 from ICEBERG (NCT02305147) and 88 were taken from study that is henceforth referred 
to as AETIONOMY  PD75. We call the union of the 303 idiopathic PD patients integrated AETIONOMY PD in the 
following. The datasets are cross-sectional and include typical clinical outcome variables, such as MDS-UPDRS, 
Hoehn and Yahr stage, cognitive assessment scores (MMSE, MOCA), Epworth sleepiness scale (ESS), REM sleep 
behavior disorder (RBD), Hospital anxiety, and depression scale (HADS). An overview about key demographic 
and clinical features of this study can be found in Table 2.
Identification of common molecular mechanisms. Common molecular mechanisms between AD 
and PD were identified with the help of a systematic literature mining approach with post-hoc manual curation. 
More specifically, the text mining engine  SCAIView76 was used to construct cause-effect relationships between 
molecules, pathways, biological processes and imaging features in both, AD and PD, see Domingo-Fernandez 
et al. and Kodamullil et al. for  details52,77 for details. After manual curation, two computable disease maps, one 
for AD and one PD were created. Finally, we have also made them interactively usable via a dedicated web appli-
cation (https ://neuro mmsig .scai.fraun hofer .de/).
Calculation of the intersection of cause-effect relationships described in the AD and PD disease maps resulted 
into 27 genes grouped into 15 cause-effect relationship sub-graphs, called mechanisms from now on (see Fig. 2 
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and https ://clus2 bio.scai.fraun hofer .de/mecha nisms for an interactive view). While some of these mechanisms 
describe only posttranslational modifications of a single protein, others reflect more complex protein–protein 
interactions and signaling cascades (Table S1). Key proteins described in both diseases include e.g. APOE, TAU, 
SNCA and TOMM40. These proteins are involved into several known disease relevant processes that we have 
made computationally accessible via our earlier developed NeuroMMSig  database52.
We mapped 148 genetic variants (SNPs) measured in ADNI1, ADNI2/GO as well as PPMI to the 27 com-
mon AD/PD disease genes via a combination of two strategies: a) proximity (using a 10 kbp window size); and 
b) eQTL mapping, see details in Supplements on page 2.
Calculation of SNP burden on molecular mechanism level. SNP data is inherently extremely sparse, 
i.e. even “common” genetic variants are comparably seldom in the data. This imposes a major challenge for any 
clustering algorithm, because the distance between two arbitrary SNP profiles based on the usual 0, 1, 2 encod-
ing then becomes almost identical. That means clustering of raw SNP profiles is prone to become statistically 
unstable and noisy. To account for this fact, we embedded the 148 SNP profiles of AD and PD patients into a 
lower dimensional latent space while taking into account the grouping of SNPs according to 15 molecular cause-
effect relationship subgraphs (aka molecular mechanisms) defined in the last section. We aimed for making this 
embedding non-linear to capture SNP-SNP interactions. Very recently, autoencoder networks (a specific deep 
learning technique) have been proposed for that  purpose78,79. Autoencoders allow for learning a non-linear and 
low dimensional representation of SNP data for each patient, i.e. in essence a SNP burden score per mechanism 
(see Supplements for details). Based on the SNP burden scores a grouping of AD and PD patients can be estab-
lished via clustering. Details will be explained later.
To maximize the chance for a later interpretation of the clustering and to avoid an imbalance due to differ-
ences in the number of mapped SNPs, we learned (sparse) autoencoder based SNP burden scores for each of 
the 15 mechanisms. That means we ended up with a 15 dimensional vector of genetic burden scores for each 
patient. Each of these 15 scores can be interpreted in terms of the relative contribution of each SNP to the overall 
score learned by the autoencoder network (Figures S2–S16). Details about the training procedure for our sparse 
autoencoder networks are described in the Supplementary Material on page 13.
Unsupervised machine learning for patient (Bi‑)clustering. Based on the 15 dimensional SNP bur-
den profile of each patient derived from SNP data we clustered patients. We here relied on sparse non-negative 
matrix factorization (sNMF). Briefly, sNMF factorizes a patients times mechanisms matrix X into a product of 
two non-negative matrices W and H , where W represents a sparse mapping of mechanisms to clusters and H a 
soft assignment of patients to  clusters80,81. That means, for each patient cluster it is possible to identify the most 
influencing mechanisms (see Supplements for details). Hence, sNMF effectively yields a bi-clustering. The entire 
(bi-)clustering procedure is in practice is an iterative process that is dependent on the initialization of both 
matrices and should thus be repeated a number of times (here: 50) to yield a consensus. This consensus was used 
for further analysis.
The number of clusters k corresponds to the number of columns of matrix W  and the number of rows of 
matrix H . We chose k based on inspection of three statistical criteria (proportion of ambiguously clustered pairs, 
silhouette index, cophenetic correlation) and in comparison to a randomly permuted cluster  assignment82–84. We 
then decided for the minimal number of clusters k yielding the most stable clustering solution (lowest proportion 
of ambiguously clustered pairs) that was at the same time exhibiting a significantly larger silhouette index and 
cophenetic correlation than expected by chance. Details are explained and shown in Supplements on page 28.
Validation of patient subtypes via independent studies. Figure 7 gives an overview of our overall 
validation strategy, which consists of two parts: In the first part we re-clustered patients in our merged AD/PD 
validation cohort using the same workflow that we had established for our discovery cohort, which re-confirmed 
the possible existence of 4 clusters in AD and PD (Table S5).
In the second part of our validation, we followed the idea of assigning patients in an independent study to the 
pre-existing clusters discovered in ADNI and PPMI and then measuring the degree of coherence between the 
cluster assignments and originally discovered groups. For this purpose, we here adopted an approach proposed in 
Kapp and  Tibshirani26: Following that approach we first developed a supervised machine learning classifier on the 
basis of the SNP data of patients in ADNI and PPMI. This allowed us to predict for any patient in an independ-
ent validation cohort the membership to a cluster in the discovery cohort based on the 148 SNP panel described 
above. We used an l1 penalized logistic regression (i.e. LASSO) as a classification algorithm, and we evaluated 
the prediction performance of this classifier via a conventional 10 times repeated tenfold cross-validation pro-
cedure. That means we subsequently left out 1/10 of our discovery data for testing the classifier and only trained 
on the remaining 9/10 of the data. Autoencoder training and l1 penalty hyper-parameter optimization was done 
within the cross-validation loop to prevent overoptimism. The corresponding cross-validated multi-class AUC 
of 70% is shown in Fig. 3E.
After classifier development, we were able to assign patients from independent studies to the clusters dis-
covered in our discovery cohort (ADNI + PPMI). The in-group proportion measure (IGP) proposed by Kapp 
and Tibshirani then measured the proportion of patients in the validation study, whose nearest neighbors in the 
discovery cohort had the same cluster label. An IGP closer to 1 indicates a stronger coherence of the statistical 
distribution of data in the validation cohort with the clustering of the discovery cohort. An IGP closer to zero 
indicates disagreement.
To further assess the statistical significance of observed IGP values we performed a permutation test, in which 
we randomly permuted the cluster assignment of patients and re-calculated the IGP. This was done for 1000 
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times. None of the randomly permuted cluster assignments exceeded the IGP of the original clustering, i.e. our 
obtained results were highly significant.
It is worthwhile mentioning that we also re-calculated the IGP for our integrated AETIONOMY AD and 
PD cohorts separately to exclude that the observed high coherence was only true for one of the two diseases. 
Figures S23, S24 clearly demonstrate that no corresponding biases could be observed, i.e. IGP values were in a 
comparable range.
Statistical analysis of clusters. Clinical data. Clinically observed differences between patient sub-
groups might be impaired by multiple confounding factors. To identify these confounders, we initially per-
formed a stepwise multinomial logistic regression (R-package “nnet”) with the cluster indicator as response and 
several potential confounders as predictors. This approach was chosen to account for the fact that many clinical 
variables show a highly skewed distribution. Considered confounders included:
• baseline diagnosis (ADNI),
• age (all),
• gender (all),
• marriage status (ADNI),
• education level (ADNI, ROSMAP, AETIONOMY PD),
• sub-study (ADNI1, ADNI2, ADNIGO, ADNI3; ROS, MAP),
• duration of the disease since the first diagnosis (PPMI, AETIONOMY PD, DIGPD, ICEBERG, ROSMAP),
• smoking history (AETIONOMY PD)
• coffee and alcohol consumption (AETIONOMY PD)
• ethnicity, including Spanish origin (PPMI, AETIONOMY PD, ICEBERG, DIGPD, ROSMAP), and
• prior neurological drug treatment (ROSMAP, PPMI, AETIONOMY PD, ICEBERG, DIGPD), including 
L-DOPA for PD (PPMI, AETIONOMY PD, ICEBERG, DIGPD).
The Akaike Information Criterion (AIC) was used for model selection, resulting in an “optimal” confounder 
set. It is worthwhile mentioning that none of the considered confounders demonstrated univariately significant 
association to cluster membership in any dataset according to a likelihood ratio test against the null model.
To determine the influence of clinical outcome measures (e.g. UPDRS3) in a second step we fitted a multi-
nomial logistic regression model that included in addition to the selected confounders exactly one of the clini-
cal variables of interest. In other words, there was a separate multinomial logistic regression for each clinical 
outcome measure. We then used a likelihood ratio test (Analysis of Deviance/type III ANOVA) to estimate 
the significance of the influence of the clinical variable of interest while correcting for confounders. In case of 
nominal significance (p < 0.05) we conducted a post-hoc analysis of pairwise differences between clusters using a 
Wald test. Due to multiple pairwise comparisons and the existence of several clinical variables of interest within 
each study, we jointly corrected P-values resulting from all statistical tests for multiple testing. This was done via 
Benjamini and Hochberg’s  method33. Corresponding results are shown in Tables S9–S11.
Figure 7.  Strategy for validating genetically defined patient clusters.
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Statistical analysis of longitudinal clinical data from ADNI and PPMI studies was performed via a general-
ized linear mixed model (R-package “lme4”) between each pair of clusters. For this purpose, we subtracted 
from each clinical outcome score its baseline value and divided by the standard deviation of the outcome score 
at baseline, resulting into a patient specific progression score. Two alternative approaches to model time were 
considered, namely either as a numerical value or as a categorical factor. Model selection via the AIC was used 
to choose among these alternatives. Notably, we also included an interaction effect between cluster and time to 
model potentially existing time inhomogeneous effects (none of them being significant, though). Furthermore, 
we included a random intercept for each patient. Akin to the situation for the baseline data we performed a 
stepwise regression to initially select an “optimal” confounder set. Afterwards, a type III ANOVA was conducted 
to estimate the significance of a given clinical outcome. P-values of pairwise differences between clusters were 
corrected for multiple testing correction in the same way as described before. Results of the clinical time series 
analysis are shown in Tables S12–S13.
Brain imaging. Statistical analysis of features derived from MRI imaging in ADNI and DaTSCAN in PPMI 
in principle followed the same approach as those derived from for clinical data at baseline. The only difference 
was that for analysis of MRI imaging derive features we always used age and sex as confounders, and no further 
confounders were considered. Results of the statistical analysis are shown in Tables S14–S15. For ADNI we used 
two types of imaging data:
1. 7 precalculated brain volume measurements available in the ADNIMERGE package. We used always data 
from that visit, at which the first dementia diagnosis had been given.
2. 193 subcortical brain volumes calculated from Distrieux’s parcellation approach, see details in Supplements.
All brain volume measurements were divided by intercranial volumes for normalization purposes before 
statistical analysis.
CSF biomarkers. CSF biomarkers were analyzed in the same way as clinical variables. Results are shown in 
Table S16. For ADNI AD patients we used always data from that visit, at which the first dementia diagnosis had 
been given.
Omics data. Analysis of transcriptomics (ROSMAP, PPMI), methylomics (ROSMAP, PPMI) data followed 
common practice in bioinformatics. Details are explained in the Supplements of this paper. Confounder analysis 
was done akin to clinical data. Accordingly, no confounders were identified in ROSMAP. However, initial quality 
control suggested a batch effect between the ROS and MAP sub-studies in DNA methylation data, which we cor-
rected via  ComBat85. In PPMI we used gender (RNAseq) and age (DNA methylation) as confounders. Complete 
analysis results are available under https ://clus2 bio.scai.fraun hofer .de/.
Analysis tools. We used bcftools (version 1.8) and PLINK (version 1.90b4.1) for SNP recoding from whole 
genome sequencing and genotyping data respectively.
R 3.5.1 was used for all data analyses purpose. R-package h2o (cluster version 3.26.0.2) was used for the 
autoencoder model training and logistic regression. We have used R-package NMF (version 0.21.0) for clustering. 
R-package biomart (version 2.36.1) was used for gene annotation. R-package SNPlocs.Hsapiens.dbSNP.20120608 
(version 0.99.11) was used to map genomic coordinates to rsIDs. We have used R-package ggplot2 (version 3.0.0) 
for producing all the analysis plots in addition to inbuilt tool provided by R-package NMF package (version 
0.21.0) for clustering and visualizations.
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